CIK 0001479419
- Non-accelerated filer
- Smaller reporting company
KALA BIO, Inc.
Sign in to watch- Ticker
- KALA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270604595
- Phone
- +1 781-996-5252
- Business address
- 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476
- Former names
- KALA BIO, Inc., Kala Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 46 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-03-30 | Chen Hongming Chief Scientific Officer | Exercise or conversion | +31,000 | $2.30 | $71K | 86,849 |
| 2020-03-30 | Chen Hongming Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −31,000 | 75,236 | ||
| 2020-03-16 | Bazemore Todd Chief Operating Officer | Purchase | +10,000 | $5.75 | $58K | 10,000 |
| 2020-03-13 | Grunberg Gregory Director | Purchase | +2,534,854 | $7.89 | $20.0M | 2,534,854 |
| 2020-03-13 | Shah Rajeev M. Director | Purchase | +6,337,135 | $7.89 | $50.0M | 10,874,613 |
| 2020-03-13 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +6,337,135 | $7.89 | $50.0M | 10,874,613 |
| 2020-03-11 | Paull Robert Bradley Director | Other acquisition | +1,287 | 2,361 | ||
| 2020-01-02 | Iwicki Mark T Chief Executive Officer | Grant or award · Stock Option (right to buy) | +365,000 | 365,000 | ||
| 2020-01-02 | Bazemore Todd Chief Operating Officer | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2020-01-02 | Brazzell Romulus K Chief Medical Officer | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2020-01-02 | Chen Hongming Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2020-01-02 | Reumuth Mary Chief Financial Officer | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2020-01-02 | Trachtenberg Eric | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2019-10-12 | Bazemore Todd Chief Operating Officer | Grant or award · Stock Option (right to buy) | +175,000 | 175,000 | ||
| 2019-10-12 | Trachtenberg Eric | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2019-08-19 | Rosen Howard B Director | Exercise or conversion | +2,880 | $0.68 | $2K | 2,880 |
| 2019-08-19 | Rosen Howard B Director | Exercise or conversion | +1,944 | $0.47 | $914 | 4,824 |
| 2019-08-19 | Rosen Howard B Director | Exercise or conversion · Stock Option (right to buy) | −2,880 | 0 | ||
| 2019-08-19 | Rosen Howard B Director | Exercise or conversion · Stock Option (right to buy) | −1,944 | 0 | ||
| 2019-06-05 | Rosen Howard B Director | Grant or award · Stock Option (right to buy) | +21,000 | 21,000 |
Page 18 of 19 · 378 trades